Cancer pain management: Basic therapy and treatment of breakthrough pain;Tumorschmerztherapie: Basistherapie und behandlung des durchbruchschmerzes

Onkologe

Volumn 13, Issue 9, 2007, Pages 865-878

  Nauck, F ^a   Eulitz, N ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Analgesics; Breakthrough pain; Cancer diseases; Chronic pain; Opioids

Indexed keywords

ANALGESIC AGENT; OPIATE;

ANALGESIA; CANCER; CANCER PAIN; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; PATIENT CARE; QUALITY OF LIFE; REVIEW;

EID: 34648834856     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-007-1264-2     Document Type: Review

References (31)

1. Arzneimittelkommission der Deutschen Ärzteschaft (2007) Empfehlung zur Therapie von Tumorschmerzen. Arzneiverordnung Praxis 34 [Sonderheft 1]
2. Beck AT, Ward CH, Mendelson M et al. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571
3. Bonica JJ, Wall PD, Melzack R (1985) Textbook of pain. Livingstone, Edinburgh New York
4. Cain DM, Wacnik PW, Eikmeier L et al. (2001) Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2: 15-23
5. Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82: 263-274
6. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129-138
7. De Conno F, Ripamonti C, Saita L et al. (1995) Role of rectal route in treating cancer pain: A randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13: 1004-1008
8. De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378-384
9. Diener KM (1996) Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 53: 1917-1927
10. Elsner F, Radbruch L, Sabatowski R et al. (1999) Switching opioids to transdermal fentanyl in a clinical setting. Schmerz 13: 273-278
11. Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3: 38-44
12. Hanks GW, Portenoy RK, Mac Donald N, Forbes K (1998) Difficult pain problems. In: Doyle D, Hanks GW, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 454-477
13. Honore P, Luger NM, Sabino MA et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521-528; Erratum in: Nat Med (2000) 6: 838
14. Deutsche Krebsgesellschaft (2002) Leitlinie medikamentöse Schmerztherapie. Interdisziplinäre kurz gefasste Leitlinien der Deutschen Krebsgesellschaft, der Deutschen Gesellschaft für Palliativmedizin, der Deutschen Gesellschaft zum Studium des Schmerzes und der Deutschen Interdisziplinären Vereinigung für Schmerztherapie. Kurzgefasste Interdisziplinäre Leitlinien. 3. Aufl.
15. Lichtor JL, Sevarino FB, Joshi GP et al. (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 89: 732-738
16. Lugo RA, Kern SE (2002) Clinical pharmacokinetics of Morphine. J Pain Palliative Care Pharmacother 16: 5-18
17. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2: 201-209
18. Marinangeli F, Ciccozzi A, Leonardis M et al. (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27: 409-416
19. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425-432
20. Mercadante S, Radbruch L, Caraceni A et al. (2002) Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94: 832-839
21. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273-281
22. Portenoy RK, Payne R, Coluzzi P et al. (1999) Oral transmucosal Fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303-312
23. Radbruch L, Loick G, Kiencke P et al. (1999) Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 18: 180-187
24. Radbruch L, Nauck F (2002) European Association for Palliative Care (EAPC): morphine and alternative opioids in cancer pain: the EAPC recommendations. Schmerz 16: 186-193
25. Radbruch L, Elsner F (2004) Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 53: 23-29
26. Rees E (2002) The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs 8: 304-308
27. Streisand JB, Varvel JR, Stanski DR et al. (1991) Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75: 223-229
28. Streisand JB, Busch MA, Egan TD et al. (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88: 305-309
29. Svendsen KB, Andersen S, Arnason S et al. (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9: 195-206
30. Taylor DR, Webster LR, Chun SY et al. (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal Fentanyl Citrate (OTFC®, ACTIQ®). Pain Med 8: 281-288
31. Zeppetella G, O'Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20: 87-92